https://itftherapeutics.com/press-release/itf-therapeutics-llc-announces-appointment-of-erica-l-monaco-cpa-as-chief-operating-officer/ 2026-02-26T18:31:21+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-announces-u-s-commercial-availability-of-duvyzat-givinostat-for-treatment-of-patients-with-duchenne-muscular-dystrophy/ 2026-02-26T18:33:45+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-anuncia-la-disponibilidad-comercial-de-duvyzat-givinostat-en-los-ee-uu-para-el-tratamiento-de-pacientes-con-distrofia-muscular-de-duchenne/ 2026-02-26T18:54:51+00:00 https://itftherapeutics.com/press-release/italfarmaco-receives-fda-approval-for-duvyzat-givinostat-in-duchenne-muscular-dystrophy-2/ 2026-02-26T19:06:03+00:00 https://itftherapeutics.com/press-release/results-from-italfarmaco-pivotal-phase-3-epidys-study-of-givinostat-in-duchenne-muscular-dystrophy-dmd-published-in-the-lancet-neurology/ 2026-02-26T19:17:03+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-announces-multiple-data-presentations-at-2026-mda-clinical-and-scientific-conference/ 2026-02-26T20:32:58+00:00 https://itftherapeutics.com/press-release/new-data-presented-on-givinostat-for-treatment-of-duchenne-muscular-dystrophy-at-2025-neuromuscular-study-group-annual-scientific-meeting/ 2026-02-26T20:33:43+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-announces-publication-of-positive-long-term-data-reinforcing-givinostat-efficacy-and-safety-as-a-treatment-for-duchenne-muscular-dystrophy/ 2026-02-26T20:35:11+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-to-present-patient-reported-outcome-data-for-duvyzat-givinostat-in-duchenne-muscular-dystrophy-at-ispor-2025/ 2026-02-26T20:36:35+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-presents-long-term-data-of-duvyzat-givinostat-for-treatment-of-duchenne-muscular-dystrophy-at-mda-clinical-and-scientific-conference/ 2026-02-26T20:37:04+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-announces-opening-of-new-u-s-headquarters-in-concord-massachusetts/ 2026-02-26T20:37:25+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-announces-multiple-data-presentations-at-2025-mda-clinical-and-scientific-conference/ 2026-02-26T20:40:34+00:00 https://itftherapeutics.com/press-release/itf-therapeutics-llc-presents-new-data-and-analyses-on-givinostat-for-treatment-of-duchenne-muscular-dystrophy-at-2026-mda-clinical-and-scientific-conference/ 2026-05-15T15:21:10+00:00